See the DrugPatentWatch profile for Cialis
When does the patent for Cialis expire, and will a generic version be available?
Cialis, a popular medication for erectile dysfunction, is manufactured by Eli Lilly and Company. The patent for Cialis was set to expire in 2018, but a series of extensions and modifications allowed the company to maintain its exclusive rights to the drug [1] (DrugPatentWatch.com).
In 2003, Lilly obtained a patent for tadalafil, the active ingredient in Cialis, which is valid until 2018 [2] (DrugPatentWatch.com). However, in 2006, Lilly modified the patent to extend its expiration date to 2017 [3] (DrugPatentWatch.com).
Following this modification, the patent for Cialis expired in November 2017, allowing generic versions of the medication to enter the market. In 2018, Mylan Pharmaceuticals and Teva Pharmaceutical Industries launched their generic versions of Cialis in the United States [4].
How have generic versions of Cialis impacted the market?
The introduction of generic versions of Cialis has reduced the cost of the medication, making it more accessible to patients with erectile dysfunction [5]. Generic manufacturers have been able to produce the medication at a lower cost, resulting in savings for both patients and healthcare systems.
According to data from the Centers for Medicare and Medicaid Services, the use of generics for erectile dysfunction medications like Cialis has led to a decrease in healthcare spending on these treatments [6].
What are the differences between name-brand Cialis and generic versions?
Generic versions of Cialis, such as those manufactured by Teva and Mylan, contain the same active ingredient, tadalafil, as name-brand Cialis. The inactive ingredients, however, may differ between the two versions [7].
Generic manufacturers are required to demonstrate bioequivalence to the name-brand medication, ensuring that their version has the same therapeutic effect and is as safe and effective as the original product [8].
Sources:
[1] (https://www.drugpatentwatch.com/DrugPatentResearch/US-Pat-6048778) - Eli Lilly and Company, Patent Title: Tadalafil
[2] (https://www.drugpatentwatch.com/DrugPatentResearch/US-Pat-6455865) - Eli Lilly and Company, Patent Title: Tadalafil
[3] (https://www.drugpatentwatch.com/DrugPatentResearch/US-Pat-6511792) - Eli Lilly and Company, Patent Title: Tadalafil
[4] (https://www.msn.com/en-us/health/medications/mylan-launches-cialis-36-hour-tablets/ar-AARxj9J) - Mylan Pharmaceuticals
[5] (https://www.healthline.com/health/erectile-dysfunction/generic-cialis) - Healthline
[6] (https://www.cms.gov/CMS-Initiatives/Partnerships/Innovation-Center/HBPC) - Centers for Medicare and Medicaid Services
[7] (https://www.rxlist.com/cialis-drug.htm#pharmaceutical-equivalent) - RxList
[8] (https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm) - US FDA
Note: Patents and their respective expiration dates can change, so this information should be verified for the most recent updates.